Ophthalmic devices, such as contact lenses, may incorporate myopia control optics in combination with therapeutic agents also known to control myopia to create a drug delivery mechanism to inhibit or arrest the progression of myopia in individuals. Any number of contact lenses incorporating myopia control optics may be combined with a therapeutic agent such as atropine, atropine sulphate monohydrate, and/or pirenzepine

Compositions for therapy of a diabetic symmetrical polyneuropathy a subject in need thereof the compositions comprising: an effective amount of a muscarinic acetylcholine receptor antagonist exemplified by pirenzepine telenzepine atropine or derivatives thereof or salts thereof or analogs thereof or derivatives thereof and a pharmacologically acceptable carrier. The composition may be injectable or alternatively may be applied topically or alternatively may be delivered orally. A suitable topica...

PROBLEM TO BE SOLVED: To provide a method for alleviating nausea vomiting stomach discomfort or the like which may sometimes occur at the time of administration of parathyroid hormone (PTH). SOLUTION: PTH is combined with a specified antiemetic such as teprenone pirenzepine hydrochloride and cetraxate hydrochloride. Thus nausea vomiting stomach discomfort or the like which may be caused in administration of PTH can be effectively alleviated. COPYRIGHT: (C)2012JPO&INPIT

The present invention relates to generally to the cytoprotective activity of mixed muscarinic inhibition/PARP modulation and in particular to the use of dual inhibitors of M1 muscarinic receptor and poly(ADP-ribose) polymerase (PARP) as neuroprotective medicaments particularly as medicaments for the prevention and/or treatment of neurological diseases. Particularly preferred compounds are condensed diazepinones e.g. condensed benzodiazepinones such as pirenzepine or compounds which are metaboliz...

The present invention relates to generally to the cytoprotective activity of mixed muscarinic inhibition/PARP modulation and in particular to the use of dual inhibitors of M1 muscarinic receptor and poly(ADP-ribose) polymerase (PARP) as neuroprotective medicaments particularly as medicaments for the prevention and/or treatment of neurological diseases.Particularly preferred compounds are condensed diazepinones e.g. condensed benzodiazepinones such as pirenzepine or compounds which are metabolize...

The present invention relates to generally to the cytoprotective activity of mixed muscarinic inhibition/PARP modulation and in particular to the use of dual inhibitors of M1 muscarinic receptor and poly(ADP-ribose) polymerase (PARP) as neuroprotective medicaments particularly as medicaments for the prevention and/or treatment of neurological diseases.Particularly preferred compounds are condensed diazepinones e.g. condensed benzodiazepinones such as pirenzepine or compounds which are metabolize...

Compositions for therapy of a diabetic symmetrical polyneuropathy a subject in need thereof the compositions comprising: an effective amount of a muscarinic acetylcholine receptor antagonist exemplified by pirenzepine telenzepine atropine or derivatives thereof or salts thereof or analogs thereof or derivatives thereof and a pharmacologically acceptable carrier. The composition may be injectable or alternatively may be applied topically or alternatively may be delivered orally. A suitable topica...

Compositions for therapy of a diabetic symmetrical polyneuropathy a subject in need thereof the compositions comprising: an effective amount of a muscarinic acetylcholine receptor antagonist exemplified by pirenzepine telenzepine atropine or derivatives thereof or salts thereof or analogs thereof or derivatives thereof and a pharmacologically acceptable carrier. The composition may be injectable or alternatively may be applied topically or alternatively may be delivered orally. A suitable topica...